We are pleased to announce the addition of five new Bundibugyo Ebolavirus Virus-Like Particle (VLP) products to our online catalog, providing researchers with safer, high-quality tools for filovirus vaccine development, antiviral screening, and basic virology research.
These newly available reagents include transcription-competent systems and structural VLP variants that will enable Filovirus research in BSL-2 facilities.
Newly Available Bundibugyo Ebolavirus Strains
Transcription-Competent VLPs (trVLPs)
- Bundibugyo Ebolavirus trVLP – Encoding nLuc Minigenome
- Bundibugyo Ebolavirus trVLP – Encoding eGFP Minigenome
Structural Virus-Like Particles (VLPs)
- Bundibugyo Ebolavirus VLP – VP40/GP/NP
- Bundibugyo Ebolavirus VLP – VP40/GP
- Bundibugyo Ebolavirus VLP – VP40
Supporting BSL-2 Filovirus Research
Because these Virus-Like Particles are non-infectious, they allow researchers to model key aspects of the Bundibugyo Ebolavirus lifecycle—including entry, assembly, and minigenome replication—at Biosafety Level 2 (BSL-2). This enables safe, accessible filovirus research, antiviral testing, and reporter-based quantitative assays without the requirement for high-containment BSL-4 facilities.
Available to Order Now
All five Bundibugyo Ebolavirus VLP products are now available for direct ordering through the Advanced Virology website. Researchers can review detailed product specifications, batch data, and ordering information via our online catalog.
Advanced Virology Inc. remains dedicated to expanding our portfolio with reliable, cutting-edge viral reagents designed to advance infectious disease research safely and efficiently.
Browse the new product line online today or reach out to our technical team for inquiries regarding applications, bulk availability, or custom solutions.
Follow Advanced Virology on Google